Literature DB >> 17093488

Vaccine manufacturing: challenges and solutions.

Jeffrey B Ulmer1, Ulrich Valley, Rino Rappuoli.   

Abstract

The recent influenza vaccine shortages have provided a timely reminder of the tenuous nature of the world's vaccine supply and the potential for manufacturing issues to severely disrupt vital access to important vaccines. The application of new technologies to the discovery, assessment, development and production of vaccines has the potential to prevent such occurrences and enable the introduction of new vaccines. Gene-based vaccines, virus-like particles, plant-derived vaccines and novel adjuvants and delivery systems represent promising approaches to creating safer, more potent vaccines. As a consequence, more people will have faster access to more effective vaccines against a broader spectrum of infectious diseases. However, the increased cost of producing new vaccines and regulatory uncertainty remain challenges for vaccine manufacturers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093488     DOI: 10.1038/nbt1261

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  99 in total

1.  Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches.

Authors:  Ieva Kalnciema; Dace Skrastina; Velta Ose; Paul Pumpens; Andris Zeltins
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

Review 2.  Pricing of new vaccines.

Authors:  Bruce Y Lee; Sarah M McGlone
Journal:  Hum Vaccin       Date:  2010-08

3.  Virus-mimetic nanovesicles as a versatile antigen-delivery system.

Authors:  Pengfei Zhang; Yixin Chen; Yun Zeng; Chenguang Shen; Rui Li; Zhide Guo; Shaowei Li; Qingbing Zheng; Chengchao Chu; Zhantong Wang; Zizheng Zheng; Rui Tian; Shengxiang Ge; Xianzhong Zhang; Ning-Shao Xia; Gang Liu; Xiaoyuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-26       Impact factor: 11.205

4.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

5.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 6.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

7.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 8.  Vaccines: the fourth century.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

9.  Strategies for improving influenza immunization rates among hard-to-reach populations.

Authors:  David Vlahov; Micaela H Coady; Danielle C Ompad; Sandro Galea
Journal:  J Urban Health       Date:  2007-07       Impact factor: 3.671

10.  Delivery of foreign antigens by engineered outer membrane vesicle vaccines.

Authors:  David J Chen; Nikolaus Osterrieder; Stephan M Metzger; Elizabeth Buckles; Anne M Doody; Matthew P DeLisa; David Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.